• GEHC

Earnings call: GE HealthCare reports steady growth and optimistic outlook

GE HealthCare reported Q3 2024 earnings, showing 1% organic growth, $4.9 billion revenue, with strong U.S. performance; facing challenges in China but optimistic about future growth.

• GEHC

GE HealthCare beats Q3 profit estimates on U.S. demand for medical devices

GE HealthCare's quarterly profit exceeded expectations, boosted by U.S. demand. Sales in China decline due to anti-corruption efforts, impacting overall revenue growth forecasts.

• GEHC

GE HealthCare reports mixed Q3, raises annual earnings guidance

GE HealthCare raised its 2024 earnings guidance after reporting mixed Q3 results, with EPS at $1.14, while projecting organic revenue growth amid market softness in China.

• GEHC

US FDA approves GE HealthCare's diagnostic drug for heart disease

GE HealthCare's Flyrcado, a diagnostic drug for coronary artery disease detection via PET imaging, gains FDA approval, promising improved accuracy and accessibility in early 2025.

• GEHC

UBS downgrades GE Healthcare to 'sell' citing overvaluation and China risk